Oric Pharmaceuticals Inc 2025年季度报告

(Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the quarterly period endedJune 30,2025OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the transition period from _________ to _________Commission File Number:001-39269 ORIC PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware(State or other jurisdiction of incorporation or organization)240 E. Grand Ave,2 FloorSouth San Francisco,CA(Address of principal executive offices)nd Registrant’s telephone number, including area code: (650)388-5600 Not applicable (Former name,former address, and former fiscal year, if changed since last report)Securities registered pursuant to Section 12(b) of the Act: Title of each classTradingSymbol(s)Name of each exchange on which registeredCommon Stock, $0.0001 par value per shareORICThe Nasdaq Global Select Market Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) hasbeen subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was requiredto submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and“emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Non-accelerated filer☒Emerging growth company☒ Accelerated filer☐ Smaller reporting company☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☒ Indicate by check mark whether theregistrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒As of August 5, 2025, the registrant had97,122,987shares of common stock, $0.0001 par value per share, outstanding. Table of Contents PART I.FINANCIAL INFORMATIONItem 1.Financial Statements (Unaudited)1Balance Sheets1Statements of Operations and Comprehensive Loss2Statements of Stockholders’ Equity3Statements of Cash Flows4Notes to Unaudited Financial Statements5Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations12Item 3.Quantitative and Qualitative Disclosures About Market Risk18Item 4.Controls and Procedures19 PART II.OTHER INFORMATIONItem 1.Legal ProceedingsItem 1A.Risk FactorsItem 2.Unregistered Sales of Equity Securities and Use of ProceedsItem 3.Defaults Upon Senior SecuritiesItem 4.Mine Safety DisclosuresItem 5.Other InformationItem 6.ExhibitsSIGNATURES SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This quarterly report on Form 10-Q contains forward-looking statements. All statements other than statements of historicalfacts contained in this quarterly report on Form 10-Q, including statements regarding our future results of operations and financialposition, business strategy, development plans, planned preclinical studies and clinical trials, future results of clinical trials,expected research and development costs, regulatory strategy, timing and likelihood of success, as well as plans and objectives ofmanagement for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements byterms such as “may,” “will,” “should,” “would,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,”“contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similarexpressions. Forward-looking statements contained in this quarterly report on Form 10-Q include, but are not limited to, statementsabout: •the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other positiveresults;•the timing, progress and results of preclinical studies and clinical trials for ORIC-944, ORIC-114 and other productcandidates we may develop, including statements regarding the timing of initiation and completion of studies ortrials and related preparatory work, the period during which the results of the trials will become available, and ourresearch and development programs;•the timing, scope or likelihood of regulatory filings and approvals;•the potential benefits of and activity under the company’s collaboration, licenses and othe